N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that Nuvec® loaded with Coronavirus plasmid
Open Orphan PLC are very excited about this new contract with a top 3 pharma company, this is a £4m RSV (respiratory syncytial virus) human challenge study clinical trial which
Dr James Khodabakhsh MD named Chairman of the Scientific Advisory Board at OKYO Pharma Ltd
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva
Avacta has announced its appointment of BBI Solutions, part of BBI Group (‘BBI’), to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with its partner, Cytiva (formerly
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Further evidence for the use of the EarlyCDT Lung blood test in lung cancer screening
Further to the announcement made on 7 July 2020, Braveheart is pleased to provide an update concerning the development of a COVID-19 test that Paraytec Limited is conducting with the
This RNS validates the refocus of Venn Life Sciences since Open Orphan took over the company last June to secure long-term partnership contracts which deliver recurring revenues for the business.
Lisa Anson, Chief Executive Officer of Redx Pharma, commented : “We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is
New York and London, August 3, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
